A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC)
Crossref DOI link: https://doi.org/10.1007/s13277-016-5031-0
Published Online: 2016-03-25
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Quan, Rencui
Huang, Jiaxing
Chen, Nan
Fang, Wenfeng
Hu, Zhihuang
Zhan, Jianhua
Zhou, Ting
Zhang, Li
Zhang, Hongyu
Text and Data Mining valid from 2016-03-25